BerGenBio ASA: Invitation to third quarter 2023 results webcast
Bergen, Norway, 6 November 2023 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will announce its results for the third quarter 2023 on Tuesday 14 November 2023.
BerGenBio's senior management team will provide a business update at 10:00 am CET.
The presentation will webcast live. To participate in the webcast please use the following link:
The third quarter financial report and presentation will also be made available on the Company’s website in the Investors/Financial Reports section from 7:00am CET the same day.
As part of the Rights Issue offering completed in June 2023, BerGenBio issued Warrants to the subscribers in the offering. The Warrants are tradable under the ticker BGBIS on the Oslo Stock Exchange. The holders of the Warrants can exercise the Warrants in two periods, the first of which will start on 15 November 2023 and end on 28 November 2023. Additional information about the Warrants is available on the Company’s website in the Investors/Warrants section. More details about how to exercise will be communicated by the Company before or on 15 November 2023.
Martin Olin CEO, BerGenBio ASA
Rune Skeie, CFO, BerGenBio ASA
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading Act.